


Colin Brown
Director of Research & Quality Development
The Menzies Company Limited


Developing Medicines
Helping People to Get Well, Feel Well and Stay Well




Colin Brown
Director of Research & Quality Development
The Mentholatum Company Limited



Developing Medicines

Helping People to Get Well, Feel Well and Stay Well



Colin Brown

Director of Research & Quality Development
The Mentholatum Company Limited



Developing Medicines

Helping People to Get Well, Feel Well and Stay Well

Journey - So Far.....

Chemist

Syntex Pharmaceuticals

Scientist in formulation development, pharmaceuticals and clinical trial supplies

Syntex Acquired by Quintiles (CRO) - no change to role

Chemist

Syntex Pharmaceuticals

Scientist in formulation development, pharmaceuticals and clinical trial supplies

Syntex Acquired by Quintiles (CRO) - no change to role

Journey - So Far.....

Mentholatum

R&D Manager - product development, analytical chemistry, regulatory affairs

Returned to Quintiles

Associate Director - pharmaceutical production, technical transfer, process validation, project management, business development

Returned to Mentholatum

Director of R&QD - product development, analytical chemistry, QC, QA, QP, validation, regulatory affairs, pharmacovigilance

Summary

30+ years in the industry

Team of 25 staff, predominately graduate and post-graduate scientists

Chemists, biochemists, pharmacists and microbiologists

On the Leadership Team for the company

BSc (Hons) CSci CChem MRSC

What is a Medicine?

2nd 'Limb' of the Regulation ("medicine by function")

.....anything intended to treat or prevent a medical condition.....

.....anything that possesses a pharmacological action.....




condition.....
.....anything that possesses a pharmacological
action.....




1st 'Limb' of the Regulation ("medicine by presentation")

.....anything that is presented to the
consumer as being capable of treating or
preventing a medical condition.....

Medicines - Legal Status



Medicines - Legal Status




Syntex Pharmaceuticals - POM
(cardiovascular disease, antiretrovirals, stroke, immunosuppressants)



Quintiles - POM
(all therapeutic areas, all routes of administration, all dosage forms)



Mentholatum - OTC
(topical pain relief, joint and muscle care)



Syntex Pharmaceuticals - POM
(cardiovascular disease, antiretrovirals, stroke, immunosuppressants)




Quintiles - POM
(all therapeutic areas, all routes of administration, all dosage forms)



Syntex Pharmaceuticals - POM
(cardiovascular disease, antiretrovirals, stroke, immunosuppressants)



Quintiles - POM
(all therapeutic areas, all routes of administration, all dosage forms)



Mentholatum - OTC
(topical pain relief, joint and muscle care)




Quintiles - POM

(all therapeutic areas, all routes of administration, all dosage forms)



Mentholatum - OTC

(topical pain relief, joint and muscle care)



Regulations!

Thankfully, the development and production of medicines is highly regulated

Unfortunately, regulatory requirements and standards don't really differentiate between classifications of medicines

Unlike POMs, healthcare products **CAN** be advertised to the public



- Marketing Claims!

fat free beauty enhancing
Earth-Friendly
Rapid Releasing

great HYPOALLERGENIC

new!
& IMPROVED

BIG lighter USE makes you a better person

We need.....



Evidence to Support Claims



Which Requires.....Scientists

What Makes Me Get Up Each Morning?

Consumer Healthcare makes a difference
to peoples' lives

These products enhance the quality of life
of those in pain

Consumers can feel better, be
independent and lead normal lives

YES WE GET UP EACH D

Consumer Healthcare makes a difference
to peoples' lives

These products enhance the quality of life



to peoples' lives

These products enhance the quality of life
of those in pain

Consumers can feel better, be



Consumers can feel better, be independent and lead normal lives



Everyday Challenges



Increasing costs, risks and burden of proof

Increasing technological advances

Increased consumer awareness and expectations


Increasing regulation and compliance













Collaborations



Extend reach and increase expertise

Interaction with leading research institutions



Sponsorship of PhD studentships

- 3 at University of Edinburgh
- Pioneering research

Collaborations - Objective Data





Comparison Between Intramuscular Temp Changes at 80 mins (1cm & 3cm)






Comparison Between Intramuscular Temp Changes
at 80 mins (1cm & 3cm)







Mechanical properties and force output of quadriceps muscle following eccentric exercise

Paul Kennedy¹, Lewis MacGregor², Eric Barnhill¹, A Cooper¹, L Hiscox¹, Colin Brown³, Jürgen Braun⁴, Ingolf Sack⁴, Edwin van Beek¹, Angus Hunter², Curtis L. Johnson⁵, Neil Roberts¹

1: Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, UK. 2: School of Sport, University of Stirling, Stirling, UK. 3: The Mentholatum Company, East Kilbride, Glasgow, UK. 4: Charité University, Berlin, Germany 5: Beckman Institute, University of Illinois at Urbana-Champaign, USA

Introduction

Unaccustomed intense eccentric exercise is known to produce increased passive muscle tension, reduced force output, muscle soreness and increased Creatine Kinase (CK) concentration in blood plasma¹. Damage to muscle fibre structures and subsequent release of Ca²⁺ ions into the cytoplasm causing injury contracture are thought to be the mechanism leading to increased tension. The aim of this study is to assess the mechanical properties of the quadriceps following eccentric exercise using Magnetic Resonance Elastography (MRE), and to confirm injury via Maximum Voluntary Contraction (MVC), CK blood concentration and subjective pain assessment. T2 weighted imaging is used to detect hyper-intense signal, which suggests oedema is present. The cross-sectional view of the thigh also allows the distribution of muscle damage to be observed via MRE and T2 imaging.

Method

20 healthy male subjects (mean age 24.1± 4.3yrs) underwent MRI scanning and functional testing 24 hours before and again 48 hours after completion of a standardised eccentric exercise protocol, when the effects of EIMD are expected to peak². Functional testing is undertaken on three further occasions over the next 9 days following the exercise protocol to track recovery. Multi-frequency MRE data at 25Hz, 37.5 Hz, 50Hz and 62.5Hz vibration frequency, and high resolution T2 weighted data are acquired during each scanning session. MR imaging is carried out on a 3T Siemens Verio scanner using a 32 channel receiver coil (InVivo). Functional testing is undertaken using a Biodex isokinetic dynamometer (Figure 1).



Figure 1: Subject seated in Biodex dynamometer. The leg rests on a mechanical arm and is secured with a Velcro cuff.

The exercise protocol is tailored to each subject based on their peak eccentric and concentric force output. A work target is determined and 12 sets of eccentric contractions are completed in as few reps as possible.

MRE phase unwrapping and mathematical inversion is carried out using custom software previously described³

Results




Figure 2: T2 weighted and magnitude stiffness elastograms of a selection of subjects who displayed oedema (A-F). The yellow line through image C depicts the plane through which a sagittal scan was prescribed (Figure 3).




Figure 3: Sagittal slice exhibiting hyper-intense signal present throughout the RF muscle length.




Figure 4 (above): RF stiffness measurements before and 48 hours after damage.

Figure 5 (above): MVC time course of moderate and severe EIMD groups

Figure 6 (above): MVC force trace at baseline and 48 hours after damage.




Figure 7 (above): Reqs required to complete each set of the eccentric exercise protocol.




Figure 8 (above): CK concentration time course. Concentration peaks 7 days post exercise.




Figure 9 (above): Reqs required to complete each set of the eccentric exercise protocol.

- A moderate and severe EIMD group were defined based on MVC values (>10% force loss=moderate EIMD) and T2 weighted images (T2 hyper-intensity=severe EIMD) (Figure 2). Group definition is supported by analysis of reps required per set (Figure 7)
- Rectus femoris (RF) muscle is found to significantly increase following eccentric exercise over both moderate (6% increase, $p=0.02$) and severe EIMD groups (45% increase, $p=0.005$) (Figure 4).
- Severe EIMD subjects exhibited a 14% ($p=0.01$) stiffness increase in the vastus intermedius (VI) muscle, consistent with localised hyper-intensity seen on the T2 images.
- Average force reduction following eccentric exercise is 24% ($p<0.001$) in the moderate EIMD group and 48% ($p>0.001$) in the severe EIMD group. MVC values recover to baseline levels after 7 days in the moderate EIMD group but fail to recover within the sampling window in the severe EIMD group (Figure 5).
- CK time course analysis shows a significant increase after 48 hours, peaking at 7 days post damage ($p>0.001$).
- Subjective pain measurements indicate a significant pain increase after 48 hours during flexion and extension ($p<0.01$).

Conclusion

MRE is capable of detecting muscle stiffness increases following eccentric exercise. T2 hyper-intensity suggestive of oedema may increase passive mechanical properties as seen in the RF and VI muscle groups in the severe EIMD subjects. Significant stiffness increase is also detected in the absence of T2 hyper-intensity, indicating that there are several mechanisms contributing to stiffness increase after eccentric damage. The discovery of localised damage in the RF following this method of eccentric exercise is significant. The vastus lateralis muscle group is predominantly studied to assess muscle properties following exercise and disease⁴, however our results suggest the main effect may be missed if the RF is not investigated.

2520. Mechanical Properties and Force Output of Quadriceps Muscle Following Eccentric Exercise

P Kennedy¹, L MacGregor², E Barnhill¹, A Cooper¹, L Hiscox¹, C Brown³, J Braun⁴, I Sack⁴, E van Beek¹, A Hunter², CL Johnson⁵, N Roberts¹

¹Clinical Research Imaging Centre (CRIC), University of Edinburgh, Edinburgh, United Kingdom; ²School of Sport, University of Stirling, Stirling, United Kingdom; ³The Mentholatum Company Ltd., Glasgow, United Kingdom; ⁴Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany; ⁵Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, IL, United States

IOP PUBLISHING

Physiol. Meas. **34** (2013) 1675–1698

PHYSIOLOGICAL MEASUREMENT

[doi:10.1088/0967-3334/34/12/1675](https://doi.org/10.1088/0967-3334/34/12/1675)

Statistical mapping of the effect of knee extension on thigh muscle viscoelastic properties using magnetic resonance elastography

Eric Barnhill¹, Paul Kennedy¹, Steven Hammer², Edwin J R van Beek¹, Colin Brown³ and Neil Roberts¹

¹ Clinical Research Imaging Centre (CRIC), College of Medicine and Veterinary Medicine, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

² Institute of Mechanical, Process and Energy Engineering, School of Engineering and Physical Sciences, Heriot-Watt University, James Nasmyth Building, Edinburgh EH14 4AS, UK

³ Research and Development, The Mentholatum Company, East Kilbride G74 5PE, UK

Consumer Healthcare

NOT about saving patients' lives

NOT as glamorous as so-called ethical pharmaceuticals

NOT involved in discovering new chemical entities


NOT involved in exotic formulations or novel modes of action



NOT as glamorous as so-called

NOT involved in discovering new chemical entities

NOT involved in exotic formulations or novel modes of action



NOT as glamorous as so-called ethical pharmaceuticals

NOT involved in discovering new chemical entities

NOT involved in exotic formulations or novel modes of action



BUT consumer healthcare is definitely professionally challenging and rewarding

Making a Difference

.....by improving quality of life

.....improving product quality

.....by developing next generation products

.....by embracing novel technologies

.....by improving patient compliance


Testimonials

"My back is no longer painful and I can take my dog for a walk again"


"I applied your product to my joints and I can't believe how quickly it worked"


"I used to get sore joints after walking or gardening - but not any longer!"


SUMMIT



Dear Sir,

I thought I should write to you as my husband of 91 years of age is fortunately, physically and mentally very active, is a great advertisement  'Deep Relief'. For the past 4 years he has used it regularly every day on his left leg, where the arthritis is most active. On the odd occasion he forgets to apply it, he finds walking very painful.

He always has 2 or 3 tubes in store and friends and neighbours who complain of their aches and pains are quickly told of the benefits of 'Deep Relief' and sometimes presented with a tube. 

He is a walking example of an active old age, thanks partly due to your product 
Yours Sincerely,
(Mrs) Pauline Richards



014 3AM

World Cancer Research Fund (WCRF UK)
www.wcrf-uk.org/learn

DEAR SIR OR MADAM
I would like to tell you
that I have been using
REG-ENOVA CAPSULES
FOR OVER TWO YEARS
IT HAS CHANGED MY
LIFE: IT HAS TAKEN
AWAY PAIN IN MY KNEE
AND HELPED ME TO GO
OUT ABOUT ON BUSES
WHICH I COULD NOT

do be fore. I have
been telling my friends about
it. HOPE this helps you
to know the product
is very good. THANKS
FOR MAKING REG-ENOVA
YOUR SINCERELY
HAZEL BARKER

I would like to tell you
that I have been using
REGENOUET CAPSULES

FOR OVER TWO YEARS
IT HAS CHANGED MY
LIFE. IT HAS TAKEN
AWAY PAIN IN MY KNEE
AND HELPED ME TO GO
OUT ABOUT ON BUSES
WHICH I COULD NOT

Thank you for listening!

do be fore I HAVE
HAPPY MY FRIENDS who
Hoping this helps you
to know the product
is very good. THANKS
FOR MAKING REGENCURE
YOUR SINCERELY
-JEL BARKER

Thank you for listening!

Colin Brown
Director of Research & Quality Development
The Mentholatum Company Limited



Developing Medicines

Helping People to Get Well, Feel Well and Stay Well

